pharma news today obesity drugs glp-1 october 2025 Eli Lilly set to leapfrog Novo Nordisk in weight-loss drug race The outlook for obesity from
Description
In a phase 2 study, amycretin showed a mean weight reduction of up to 24.3%, which is comparable to or even greater than the weight loss seen with tirzepatide and similar to the results for retatrutide
Medically supervised GLP-1 weight loss in Oswego, IL
The key takeaway
/PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly...
A recent study tracked self-reported GLP-1 side effects among Reddit users and found several overlooked side effects like chills and hot flashes linked to weight loss medications like Ozempic and Mounjaro.
Alluloss Plus+ Daily Wellness Blend
